Medibank (ASX:MPL) share price lifts despite rumours of failed hospital bid

Here are all the details on Medibank's supposed failed acquisition.

Key points
  • The Medibank share price is up 0.7% today, trading at $3.23
  • That's despite reports the company's rumoured acquisition of a stake in Cura Group has failed
  • It was previously reported the insurer was planning to announce the purchase before the release of its half year results

The Medibank Private Ltd (ASX: MPL) share price is in the green today despite talk its bid for day hospital operator Cura Group, has fallen through.

Previously, it was reported the private health insurer might have been gearing up to release news of the acquisition in time for its half year results – set to drop next Friday.

At the time of writing, the Medibank share price is $3.23, 0.78% higher than its previous close.

For comparison, the S&P/ASX 200 Index (ASX: XJO) has slipped 0.8% this morning.

Let's take a look at the latest rumours surrounding Medibank.

Private health insurance diagram.

Image source: Getty Images

Medibank's rumoured acquisition falls through

The Medibank share price appears unfazed by rumours its acquisition of private day hospital asset Cura has failed.

The private insurer was previously reported to have agreed to buy a stake in the business for an undetermined amount.

However, The Australian today reported the deal has been abandoned prior to settling.

Cura owns day hospitals in every Australian state and in the Australian Capital Territory (ACT).

Its crown jewels include Barton Private Hospital, Sydney Day Surgery Prince Alfred, and Somerset Private Hospital.

According to the publication, while the proposed acquisition's cost was unknown, when Fresenius Medical Care purchased its majority holding in Cura – reported to be 70% – in 2017, it valued the hospital operator at $400 million.

While the publication didn't confirm how big of a stake in Cura that Medibank was rumoured to be purchasing, Fresenius Medical Care hit back at initial reports it was offloading any of its stake. The company said:

Fresenius Medical Care is strongly committed to long-term ownership and continues to be deeply invested in growing the Cura Day Hospitals business. There is no plan to change this approach in the foreseeable future.

Medibank share price snapshot

While it's gaining today, this year so far has been rough on the Medibank share price.

It has fallen 5% since the start of 2022.

Though, it's currently 14% higher than it was this time last year.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Two scientists analysing results on a computer screen.
Healthcare Shares

$10,000 invested in Pro Medicus and CSL shares 3 years ago is now worth…

Was I better off investing $10,000 into Pro Medicus or CSL shares three years ago?

Read more »

A share market investment manager monitors share price movements on his mobile phone and laptop
Healthcare Shares

Fund managers are loading up on CSL shares. Here's why

CSL is attracting renewed interest from fundies.

Read more »

Happy businessman fist pumping while looking at a tablet.
Healthcare Shares

Mesoblast wins FDA nod for new Ryoncil potency test

Mesoblast gets FDA approval for a new Ryoncil potency assay, aiming to ensure quality and support product expansion.

Read more »

Scientists in a laboratory look at a computer screen with anticipation on their faces.
Healthcare Shares

Can CSL shares hit $200? 3 things that need to go right

CSL needs to prove its earnings engine is accelerating again, not merely stabilising.

Read more »

Group of doctors celebrate by pumping fists in the air.
Healthcare Shares

Telix Pharmaceuticals vs Ramsay Healthcare: Which ASX healthcare stock made investors richer in 2026?

And find out which has the strongest upside ahead.

Read more »

Buy and sell written on red dice on top of stock market charts.
Broker Notes

Up 98%: Are CSL shares now a buy, hold or sell?

A leading expert provides his forecast for CSL’s rocketing shares.

Read more »

Doctor with stethoscope using a tablet in a hospital.
Broker Notes

What is this broker's view on Telix shares after yesterday's crash?

Here is the latest outlook from Bell Potter.

Read more »

Doctor with stethoscope holding a tablet and smiling.
Healthcare Shares

How much could the CSL share price rise in the next year?

Can CSL continue delivering very healthy returns?

Read more »